Dr Ian Hudson, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), has announced he is to leave his role in September 2019.
Dr Hudson said: “My reasons for stepping down are both personal and professional. I had always intended to reduce my total work commitment to enable me to pursue other things and perhaps have more of a portfolio career by the time I reached 60, which has now happened. I feel the time is right for a new person to guide the Agency and our work through its next phase, following the UK’s departure from the European Union next year.
“Although I will be standing down next autumn, my focus remains on ensuring the Agency delivers its essential contribution to public health, and I look forward to continuing to lead our work until September 2019.”
Dr Hudson has been at the MHRA for 17 years, serving as CEO for the last five years. He was promoted from his role as MHRA’s Licensing Director in 2013, where he was responsible for the majority of medicines licensing activities.
He practised as a paediatrician for a number of years before working in the pharmaceutical industry in clinical research and development between 1989 and 2001, when he joined the MCA (Medicines Control Agency) as Director of the Licensing Division. He is the CHMP (Committee for Human Medicinal Products) delegate for the UK.
Recruitment for his successor will begin early in 2019, so that an orderly handover can be arranged once an appointment has been made.